Chemomab Therapeutics (CMMB) Operating Leases (2019 - 2025)
Chemomab Therapeutics' (CMMB) quarterly Operating Leases came in at $179000.0 in Q1 2025, down 36.07% YoY from $280000.0 in Q1 2024, and down 44.75% on a QoQ basis from $324000.0 in Q4 2024.
Chemomab Therapeutics (CMMB) Operating Leases (2019 - 2025) Analysis & Trends
Chemomab Therapeutics (CMMB) has 7 years of Operating Leases data on file, last reported at $179000.0 in Q1 2025.
- Quarterly Operating Leases fell 36.07% year-over-year to $179000.0 in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $179000.0 (down 36.07% YoY) and the FY2024 annual result came in at $324000.0, down 17.35% from the prior year.
- Operating Leases slipped to $179000.0 in Q1 2025, from $324000.0 in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $392000.0 in Q4 2023 to a low of $5000.0 in Q3 2023.
- A 5-year average of $219294.1 and a median of $230000.0 in 2024 frame the typical range for Operating Leases.
- Annual changes were most pronounced in 2023 — Operating Leases slumped 95.76% — and 2024, when it jumped 4500.0%.
- Tracing CMMB's Operating Leases over 5 years: stood at $343000.0 in 2021, then sank by 37.61% to $214000.0 in 2022, then surged by 83.18% to $392000.0 in 2023, then dropped by 17.35% to $324000.0 in 2024, then slumped by 44.75% to $179000.0 in 2025.
- The last three Operating Leases figures came in at $179000.0 (Q1 2025), $324000.0 (Q4 2024), and $230000.0 (Q3 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Chemomab Therapeutics | 13.33 Mn | 2.96 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 179,000.00 |
| Dec 31, 2024 | 324,000.00 |
| Sep 30, 2024 | 230,000.00 |
| Jun 30, 2024 | 251,000.00 |
| Mar 31, 2024 | 280,000.00 |
| Dec 31, 2023 | 392,000.00 |
| Sep 30, 2023 | 5,000.00 |
| Jun 30, 2023 | 33,000.00 |
| Mar 31, 2023 | 62,000.00 |
| Dec 31, 2022 | 214,000.00 |
| Sep 30, 2022 | 118,000.00 |
| Jun 30, 2022 | 148,000.00 |
| Mar 31, 2022 | 203,000.00 |
| Dec 31, 2021 | 343,000.00 |
| Sep 30, 2021 | 298,000.00 |
| Jun 30, 2021 | 320,000.00 |
| Mar 31, 2021 | 328,000.00 |
| Dec 31, 2020 | 358,000.00 |
| Sep 30, 2020 | 63,000.00 |
| Jun 30, 2020 | 108,000.00 |